Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02809326 · ClinicalTrials.gov registry record · Phase 2
Trauma Management Therapy for OEF and OIF Combat Veterans
A Phase 2 study, sponsored by University of Central Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT02809326: Completed Phase 2 study, sponsored by University of Central Florida.
NCT02809326 is a Phase 2 study that has completed, run by University of Central Florida. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02809326, a Phase 2 study, has completed, sponsored by University of Central Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
This trial will evaluate the efficacy and efficiency of Trauma Management Therapy (TMT; Frueh, Turner, Beidel, 1996; Beidel, Frueh, Uhde, under preparation), which combines individual virtual reality (VR) assisted exposure therapy with group social and emotional rehabilitation skills training (will be superior to a treatment consisting of the same VR- exposure and group psychoeducational group therapy. TMT will be conducted in traditional 17-week format, and a 3-week intensive treatment format. Outcome will be assessed using relevant clinical, process, and cost outcomes. Additionally, investigators will assess the potential of olfactory stimulation as a trigger for PTSD symptoms of intrusive thoughts and re-experiencing. Therefore, this proposal will integrate clinical and neurobiological assessment studies designed to understand the role of these factors in the etiology, maintenance, and treatment of PTSD.
Primary Outcome
PTSD Symptom Severity
Interventions
- BEHAVIORAL 17 week Exposure Therapy Control Arm
- BEHAVIORAL Trauma Management Therapy
- BEHAVIORAL Intensive 3-Week Trauma Management Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02809326 record still lists
NCT02809326 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 3 interventions - of which 17 week Exposure Therapy Control Arm is the first listed.
NCT02809326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02809326 about?
NCT02809326 is a clinical study titled "Trauma Management Therapy for OEF and OIF Combat Veterans". This trial will evaluate the efficacy and efficiency of Trauma Management Therapy (TMT; Frueh, Turner, Beidel, 1996; Beidel, Frueh, Uhde, under preparation), which combines individual virtual reality (VR) assisted exposure therapy with group social and emotional rehabilitation skills training (will ...
What is the current status of trial NCT02809326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2015-11. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02809326?
The interventions under investigation include: 17 week Exposure Therapy Control Arm (BEHAVIORAL), Trauma Management Therapy (BEHAVIORAL), Intensive 3-Week Trauma Management Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT02809326?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02809326's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia